Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18818926 | 2-(5-AMINOPYRIDIN-2-YL)-N-BENZYLACETAMIDES AND USE THEREOF IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA | August 2024 | March 2025 | Allow | 6 | 1 | 0 | No | No |
| 18670604 | METHOD OF TREATMENT OF DEPRESSED PATIENTS WITH POOR COGNITION AND SELECTION OF OTHER PATIENTS BENEFITING FROM A BENZYLPIPERAZINE-AMINOPYRIDINE AGENT | May 2024 | April 2025 | Abandon | 11 | 1 | 0 | No | No |
| 18670580 | METHOD OF TREATMENT OF DEPRESSED PATIENTS WITH POOR COGNITION AND SELECTION OF OTHER PATIENTS BENEFITING FROM A BENZYLPIPERAZINE-AMINOPYRIDINE AGENT | May 2024 | March 2025 | Abandon | 9 | 1 | 0 | No | No |
| 18670588 | METHOD OF TREATMENT OF DEPRESSED PATIENTS WITH POOR COGNITION AND SELECTION OF OTHER PATIENTS BENEFITING FROM A BENZYLPIPERAZINE-AMINOPYRIDINE AGENT | May 2024 | March 2025 | Abandon | 9 | 1 | 0 | No | No |
| 18583976 | S-ENANTIOMERICALLY ENRICHED COMPOSITIONS OF BETA BLOCKERS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | February 2024 | March 2025 | Allow | 13 | 1 | 0 | No | No |
| 18425984 | 6'(4-METHOXYPHENYL)-2'-ALKOXY-3,4'-BIPYRIDINE-3'-CARBONITRILE AS ANTIMICROBIAL COMPOUNDS | January 2024 | June 2024 | Allow | 60 | 0 | 0 | No | No |
| 18425923 | 6'(4-METHOXYPHENYL)-2'-ALKOXY-3,4'-BIPYRIDINE-3'-CARBONITRILE AS ANTIMICROBIAL COMPOUNDS | January 2024 | May 2024 | Allow | 4 | 0 | 0 | No | No |
| 18420370 | TIMOLOL MALEATE GEL FOR TOPICAL ADMINISTRATION | January 2024 | January 2025 | Allow | 11 | 2 | 0 | Yes | No |
| 18408929 | TEMOZOLOMIDE COMPOUNDS, POLYMERS PREPARED THEREFROM, AND METHOD OF TREATING A DISEASE | January 2024 | April 2025 | Allow | 15 | 1 | 1 | No | No |
| 18390164 | METHODS OF TREATING HYPOGONADISM WITH TRANSNASAL TESTOSTERONE BIO-ADHESIVE GEL FORMULATIONS IN MALE WITH ALLERGIC RHINITIS, AND METHODS FOR PREVENTING AN ALLERGIC RHINITIS EVENT | December 2023 | March 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18381112 | 2,16-DIOXAPENTACYCLO[7.7.5.01,21.03,8.010,15]HENICOSA 3(8),10,12,14-TETRAENE-7,20-DIONE AS AN ANTIMICROBIAL COMPOUND | October 2023 | September 2024 | Abandon | 11 | 1 | 1 | No | No |
| 18379906 | 6'(4-METHOXYPHENYL)-2'-ALKOXY-3,4'-BIPYRIDINE-3'-CARBONITRILE AS ANTIMICROBIAL COMPOUNDS | October 2023 | April 2024 | Allow | 6 | 1 | 1 | No | No |
| 18235029 | PYRIDO[3",4":4',5']PYRROLO[3',2':4,5]IMIDAZOLE[1,2-C]PYRIMIDINE COMPOUNDS AS CK2 INHIBITORS | August 2023 | December 2023 | Allow | 4 | 0 | 1 | Yes | No |
| 18451702 | INDOLIN-2-ONE OR PYRROLO -PYRIDIN -2 -ONE DERIVATIVES | August 2023 | February 2025 | Abandon | 18 | 0 | 1 | No | No |
| 18222565 | PYRIDO[4',3':4,5]PYRROLO[3,2-B][1,7]NAPHTHYRIDINE COMPOUNDS AS CK2 INHIBITORS | July 2023 | January 2024 | Allow | 6 | 0 | 1 | Yes | No |
| 18200251 | CANCER THERAPEUTIC | May 2023 | April 2025 | Abandon | 23 | 0 | 1 | No | No |
| 18141834 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | May 2023 | May 2025 | Allow | 25 | 2 | 0 | No | No |
| 18305825 | ARIPIPRAZOLE INJECTABLE SUSPENSION FORMULATION HAVING PROLONGED SHELF LIFE | April 2023 | June 2025 | Allow | 26 | 2 | 0 | No | No |
| 18299493 | PHARMACEUTICAL COMPOSITIONS OF TESTOSTERONE | April 2023 | August 2024 | Allow | 16 | 2 | 0 | Yes | No |
| 18176533 | CARBOSTYRIL DERIVATIVES AND MOOD STABILIZERS FOR TREATING MOOD DISORDERS | March 2023 | February 2025 | Abandon | 23 | 1 | 0 | No | No |
| 18097648 | TRANSDERMAL DRUG DELIVERY SYSTEM FOR KETAMINE | January 2023 | May 2025 | Abandon | 28 | 1 | 0 | No | No |
| 18091666 | AGENT FOR SUPPRESSING POST-SURGICAL CANCER RECURRENCE AND/OR METASTASIS | December 2022 | January 2025 | Abandon | 25 | 1 | 0 | No | No |
| 18083395 | USE OF COMPOUND OR PHARMACEUTICAL DERIVATIVE THEREOF IN INHIBITING CAMK2G PROTEIN ACTIVITY | December 2022 | March 2024 | Allow | 15 | 2 | 0 | Yes | No |
| 18079067 | METHOD OF TREATING VARIOUS DISORDERS AND CONDITIONS USING CITICOLINE | December 2022 | October 2024 | Abandon | 23 | 1 | 0 | No | No |
| 17986264 | INJECTABLE CARBAMAZEPINE COMPOSITION ESSENTIALLY FREE OF 10-BROMO-CARBAMAZEPINE | November 2022 | January 2025 | Abandon | 26 | 1 | 0 | No | No |
| 18053503 | COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC CONDITIONS | November 2022 | December 2024 | Abandon | 25 | 1 | 0 | No | No |
| 18051937 | PHARMACEUTICAL USE OF AN EXTENDED-RELEASE COMPOSITION CONTAINING PIRFENIDONE FOR THE TREATMENT AND REVERSAL OF HUMAN STEATOHEPATITIS (NAFLD/NASH) | November 2022 | December 2024 | Abandon | 25 | 1 | 0 | No | No |
| 18051060 | HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS | October 2022 | February 2025 | Abandon | 28 | 0 | 1 | No | No |
| 17961288 | COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLOGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY | October 2022 | June 2025 | Abandon | 33 | 1 | 1 | No | No |
| 17936019 | UNIVERSAL DISPERSANT | September 2022 | February 2025 | Abandon | 29 | 1 | 0 | No | No |
| 17943185 | COMPOSITIONS COMPRISING EPHEDRINE OR AN EPHEDRINE SALT AND METHODS OF MAKING AND USING SAME | September 2022 | December 2022 | Allow | 3 | 1 | 0 | No | No |
| 17886099 | PHARMACEUTICAL COMPOSITION FOR TREATING THYROID CANCER COMPRISING TYROSINE KINASE ACTIVITY INHIBITOR AS ACTIVE INGREDIENT | August 2022 | April 2024 | Allow | 20 | 0 | 0 | No | No |
| 17865697 | METHODS OF ADMINISTRATION FOR HIGHLY WATER-SOLUBLE SALTS OF A SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKER | July 2022 | January 2025 | Allow | 31 | 3 | 1 | No | No |
| 17837344 | USE OF COMPOUND OR MEDICINAL DERIVATIVE THEREOF IN INHIBITING AIM2 PROTEIN ACTIVITY | June 2022 | January 2024 | Allow | 19 | 2 | 0 | No | No |
| 17835545 | Compounds and Methods for the Treatment of Acute Myelogenous Leukemia | June 2022 | April 2024 | Allow | 22 | 2 | 1 | Yes | No |
| 17831248 | TARGETED TREATMENT OF MATURE T-CELL LYMPHOMA | June 2022 | August 2024 | Abandon | 27 | 1 | 0 | No | No |
| 17738557 | COMPOSITIONS COMPRISING EPHEDRINE OR AN EPHEDRINE SALT AND METHODS OF MAKING AND USING SAME | May 2022 | September 2022 | Allow | 4 | 1 | 1 | No | No |
| 17737508 | METHODS OF TREATMENT WITH N-((R)-1-(3-CHLOROPYRIDIN-2-YL)-2,2,2-TRIFLUOROETHYL)-2-((S)-2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLINE-5-CARBOXAMIDE | May 2022 | May 2024 | Abandon | 24 | 2 | 0 | No | No |
| 17720077 | TREATMENT OF HIDRADENITIS SUPPURATIVA USING JAK INHIBITORS | April 2022 | December 2024 | Allow | 32 | 3 | 0 | Yes | No |
| 17708466 | METHODS AND COMPOSITIONS FOR TREATMENT OF PRESBYOPIA, MYDRIASIS, AND OTHER OCULAR DISORDERS | March 2022 | February 2024 | Allow | 23 | 3 | 0 | Yes | No |
| 17698971 | COMPOUNDS FOR REGULATING TRAINED IMMUNITY, AND THEIR METHODS OF USE | March 2022 | September 2023 | Allow | 18 | 0 | 1 | Yes | No |
| 17696319 | PHARMACEUTICAL COMPOSITIONS OF TESTOSTERONE | March 2022 | March 2023 | Allow | 12 | 3 | 0 | Yes | No |
| 17692753 | TREATMENT OF GVHD | March 2022 | May 2024 | Abandon | 27 | 0 | 1 | No | No |
| 17692094 | COMBINATION PRODUCT USING 3,4-METHYLENEDIOXYMETHAMPHETAMINE AND CARVEDILOL FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | March 2022 | September 2024 | Abandon | 30 | 5 | 1 | Yes | No |
| 17640362 | THIORIDAZINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | March 2022 | February 2025 | Allow | 36 | 0 | 0 | No | No |
| 17675289 | METHODS OF TREATING PROSTATE CANCER | February 2022 | February 2024 | Abandon | 24 | 2 | 0 | No | No |
| 17650663 | COMPOSITION COMPRISING FEXOFENADINE | February 2022 | March 2024 | Abandon | 25 | 3 | 1 | No | No |
| 17667136 | METHOD FOR THE TREATMENT OF DRAVET SYNDROME | February 2022 | May 2024 | Allow | 27 | 1 | 0 | No | No |
| 17587197 | METHODS FOR THE TREATMENT OF GLIOBLASTOMA MULTIFORME | January 2022 | August 2024 | Allow | 31 | 2 | 0 | No | No |
| 17627965 | Phenyl Containing Compound, Intermediate Thereof, Preparation Method Therefor and Application Thereof | January 2022 | February 2023 | Allow | 13 | 0 | 0 | No | No |
| 17571804 | BIODEGRADABLE DRUG DELIVERY COMPOSITIONS | January 2022 | April 2024 | Abandon | 27 | 1 | 0 | No | No |
| 17569002 | TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT | January 2022 | April 2025 | Abandon | 40 | 2 | 1 | No | No |
| 17556904 | COMPOSITIONS COMPRISING EPHEDRINE OR AN EPHEDRINE SALT AND METHODS OF MAKING AND USING SAME | December 2021 | July 2022 | Allow | 7 | 1 | 1 | No | No |
| 17533528 | ANTIVIRAL THERAPEUTIC COMPOUNDS AND COMPOSITIONS FOR USE IN TREATMENT OF CORONAVIRUS AND INFLUENZA VIRUS | November 2021 | July 2023 | Allow | 20 | 1 | 0 | No | No |
| 17529427 | PERSONAL CARE COMPOSITION | November 2021 | June 2025 | Allow | 43 | 4 | 1 | No | No |
| 17608086 | METHODS OF TREATING ACUTE MYELOID LEUKEMIA WITH FARNESYLTRANSFERASE INHIBITORS | November 2021 | June 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17506772 | USE OF 1-[4-BROMO-5-[1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL]-2-FLUOROPHENYL]-3-PHENYLUREA AND ANALOGS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH GENETIC ABNORMALITIES IN PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA | October 2021 | May 2023 | Abandon | 19 | 2 | 0 | No | Yes |
| 17498879 | COMPOSITION FOR THE TREATMENT OF PSORIASIS | October 2021 | July 2023 | Abandon | 21 | 1 | 1 | No | No |
| 17490999 | TREATMENT OF MALIGNANCIES | September 2021 | February 2025 | Abandon | 41 | 2 | 0 | No | No |
| 17485581 | SMALL MOLECULES FOR INHIBITING CHEMOKINE ACTIVITY AND/OR CANCER CELLS GROWTH | September 2021 | October 2024 | Allow | 37 | 2 | 0 | Yes | No |
| 17476636 | Rosacea Treatment Method | September 2021 | January 2024 | Abandon | 28 | 1 | 0 | No | No |
| 17475914 | POLYMERIC BIOMATERIALS DERIVED FROM PHENOLIC MONOMERS AND THEIR MEDICAL USES | September 2021 | February 2024 | Allow | 29 | 1 | 1 | No | No |
| 17465697 | COMPOSITIONS COMPRISING EPHEDRINE OR AN EPHEDRINE SALT AND METHODS OF MAKING AND USING SAME | September 2021 | December 2021 | Allow | 3 | 1 | 0 | No | No |
| 17445449 | COMPOUNDS, METHODS, AND TREATMENTS FOR ABNORMAL SIGNALING PATHWAYS FOR PRENATAL AND POSTNATAL DEVELOPMENT | August 2021 | February 2025 | Allow | 42 | 2 | 1 | No | No |
| 17394984 | Biodegradable, Thermally Responsive Injectable Hydrogel for Treatment of Ischemic Cardiomyopathy | August 2021 | January 2024 | Allow | 30 | 1 | 1 | Yes | No |
| 17381770 | COMPOSITIONS COMPRISING EPHEDRINE OR AN EPHEDRINE SALT AND METHODS OF MAKING AND USING SAME | July 2021 | August 2022 | Allow | 13 | 4 | 1 | Yes | Yes |
| 17379986 | DRUG DELIVERY COMPOSITION, METHOD FORMING THE SAME AND METHOD FOR TREATING INNER EAR DISORDERS | July 2021 | July 2024 | Allow | 36 | 4 | 1 | No | No |
| 17352006 | TRANSDERMAL DRUG DELIVERY SYSTEM FOR KETAMINE | June 2021 | September 2022 | Allow | 15 | 2 | 1 | Yes | No |
| 17351003 | Methods of Treating Hypogonadism with Transnasal Testosterone Bio-Adhesive Gel Formulations in Male With Allergic Rhinitis, And Methods for Preventing An Allergic Rhinitis Event | June 2021 | December 2023 | Abandon | 30 | 1 | 0 | No | No |
| 17342148 | COMPOUNDS AND METHODS OF USING COMPOUNDS FOR TREATMENT OF RESPIRATORY DISEASES | June 2021 | May 2025 | Abandon | 47 | 2 | 1 | No | No |
| 17339569 | METHOD TO PREVENT AND TREAT OSTEOARTHRITIS BY CALCIUM CHANNEL BLOCKERS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS, AND ANGIOTENSIN RECEPTOR BLOCKERS | June 2021 | August 2023 | Abandon | 26 | 4 | 1 | No | No |
| 17336283 | Compositions for Reducing Hair Loss and/or Increasing Hair Regrowth | June 2021 | April 2024 | Allow | 34 | 2 | 0 | Yes | No |
| 17297853 | GREEN METHOD TO PREPARE PLAIN WATER-BASED POLYSACCHARIDE CHITOSAN SOLUTIONS | May 2021 | January 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17238013 | INDOLIN-2-ONE OR PYRROLO -PYRIDIN -2 -ONE DERIVATIVES | April 2021 | October 2023 | Abandon | 30 | 0 | 1 | No | No |
| 17231789 | S-ENANTIOMERICALLY ENRICHED COMPOSITIONS OF BETA BLOCKERS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | April 2021 | November 2023 | Allow | 31 | 2 | 0 | No | No |
| 17230270 | METHODS AND COMPOSITIONS FOR TREATMENT OF PRESBYOPIA, MYDRIASIS, AND OTHER OCULAR DISORDERS | April 2021 | July 2024 | Allow | 40 | 3 | 0 | No | No |
| 17212845 | 2-(4-{1-[6-(4-Isopropyl-phenyl)-imidazo[2,1-b][1,3,4]thiadiazol-2-yl]-piperidin-4-ylmethyl}-piperazin-1-yl)-ethanol and use thereof | March 2021 | February 2024 | Allow | 35 | 0 | 1 | No | No |
| 17210699 | MELFLUFEN DOSAGE REGIMENS FOR CANCER | March 2021 | November 2024 | Abandon | 44 | 2 | 0 | No | Yes |
| 17199270 | HEPAROSAN POLYMERS AND METHODS OF MAKING AND USING SAME FOR THE ENHANCEMENT OF THERPEUTICS | March 2021 | September 2023 | Abandon | 30 | 1 | 0 | No | No |
| 17189552 | GHRELIN RECEPTOR AGONIST FOR TREATMENT OF CACHEXIA | March 2021 | July 2023 | Abandon | 28 | 0 | 1 | No | No |
| 17188162 | TEMOZOLOMIDE COMPOUNDS, POLYMERS PREPARED THEREFROM, AND METHOD OF TREATING A DISEASE | March 2021 | November 2023 | Allow | 32 | 2 | 1 | Yes | No |
| 17185238 | Therapeutic Compositions | February 2021 | May 2023 | Abandon | 27 | 1 | 0 | No | No |
| 17181976 | COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLOGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY | February 2021 | May 2023 | Abandon | 26 | 0 | 1 | No | No |
| 17167395 | METHODS AND SYSTEMS FOR TREATING VITILIGO USING PHLOROGLUCINOL AND RELATED COMPOSITIONS | February 2021 | November 2023 | Abandon | 33 | 2 | 0 | No | No |
| 17166672 | Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects | February 2021 | May 2024 | Abandon | 39 | 2 | 1 | No | No |
| 17156894 | Method Of Treatment Of Obesity | January 2021 | March 2024 | Allow | 38 | 3 | 1 | No | No |
| 17136870 | FIXED DOSE COMBINATIONS AND FORMULATIONS COMPRISING ETC1002 AND EZETIMIBE AND METHODS OF TREATING OR REDUCING THE RISK OF CARDIOVASCULAR DISEASE | December 2020 | May 2023 | Allow | 29 | 1 | 0 | No | No |
| 17135883 | METHOD FOR TREATMENT OF CANCER WITH COMBINATION OF COLD ATMOSPHERIC PLASMA AND A GENE INHIBOTOR | December 2020 | March 2024 | Allow | 39 | 2 | 1 | No | No |
| 17254099 | Base-Modified Cytidine Nucleotides for Leukemia Therapy | December 2020 | June 2024 | Abandon | 42 | 1 | 1 | No | No |
| 17106908 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | November 2020 | November 2023 | Abandon | 36 | 2 | 1 | No | No |
| 17106584 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | November 2020 | January 2023 | Allow | 26 | 1 | 0 | No | No |
| 17104402 | TREATMENT OF SEXUAL DYSFUNCTION | November 2020 | April 2023 | Abandon | 29 | 0 | 1 | No | No |
| 16952529 | SPHINGOSINE PATHWAY MODULATING COMPOUNDS FOR THE TREATMENT OF CANCERS | November 2020 | August 2023 | Allow | 33 | 2 | 0 | No | No |
| 17099268 | Mito-Honokiol Compounds and Methods of Synthesis and Use Thereof | November 2020 | September 2023 | Allow | 34 | 1 | 1 | No | No |
| 16949571 | CARBOSTYRIL DERIVATIVES AND MOOD STABILIZERS FOR TREATING MOOD DISORDERS | November 2020 | March 2023 | Abandon | 29 | 1 | 0 | No | No |
| 17084689 | IPN hydrogel for preparation and application | October 2020 | March 2023 | Abandon | 28 | 1 | 0 | No | No |
| 17074120 | COMBINATION OF RIBOCICLIB AND DABRAFENIB FOR TREATING OR PREVENTING CANCER | October 2020 | March 2023 | Abandon | 29 | 0 | 1 | No | No |
| 17048361 | NEW THERAPEUTIC USES | October 2020 | August 2024 | Abandon | 46 | 3 | 0 | No | No |
| 17071273 | IMIDAZO-FUSED HETEROCYCLES AND USES THEREOF | October 2020 | August 2023 | Allow | 34 | 1 | 1 | No | No |
| 17070493 | BIODEGRADABLE DRUG DELIVERY COMPOSITIONS | October 2020 | December 2022 | Abandon | 26 | 2 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner KANTAMNENI, SHOBHA.
With a 16.7% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 12.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner KANTAMNENI, SHOBHA works in Art Unit 1627 and has examined 837 patent applications in our dataset. With an allowance rate of 33.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 37 months.
Examiner KANTAMNENI, SHOBHA's allowance rate of 33.1% places them in the 2% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by KANTAMNENI, SHOBHA receive 2.81 office actions before reaching final disposition. This places the examiner in the 92% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by KANTAMNENI, SHOBHA is 37 months. This places the examiner in the 13% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +34.7% benefit to allowance rate for applications examined by KANTAMNENI, SHOBHA. This interview benefit is in the 85% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 10.6% of applications are subsequently allowed. This success rate is in the 2% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 24.8% of cases where such amendments are filed. This entry rate is in the 25% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 42.1% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 37% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 50.6% of appeals filed. This is in the 16% percentile among all examiners. Of these withdrawals, 58.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 48.3% are granted (fully or in part). This grant rate is in the 57% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.5% of allowed cases (in the 59% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.